Summary
Boston Scientific Corporation (BSX) reported a net loss of $354 million, or $0.26 per share, for the first quarter of 2013, a significant decrease compared to a net income of $113 million, or $0.08 per share, in the prior year's quarter. This loss was heavily influenced by a substantial $423 million goodwill impairment charge related to the Cardiac Rhythm Management (CRM) reporting unit, stemming from a recent business reorganization. Excluding this and other non-recurring charges, adjusted net income was $224 million, or $0.16 per share. Net sales saw a decline of 6% to $1.761 billion, impacted by foreign currency headwinds and divestitures. However, excluding these factors, net sales decreased by 4%. Gross profit margin improved to 67.2% from 66.2% year-over-year, driven by manufacturing efficiencies and the favorable product mix from newer stent technologies, partially offset by pricing pressures. The company continues to manage its debt effectively and maintain compliance with its credit facility covenants.
Financial Highlights
51 data points| Revenue | $1.76B |
| Cost of Revenue | $578.00M |
| Gross Profit | $1.18B |
| SG&A Expenses | $631.00M |
| Operating Expenses | $1.51B |
| Operating Income | -$330.00M |
| Interest Expense | $65.00M |
| Net Income | -$354.00M |
| EPS (Basic) | $-0.26 |
| EPS (Diluted) | $-0.26 |
| Shares Outstanding (Basic) | 1.35B |
| Shares Outstanding (Diluted) | 1.35B |
Key Highlights
- 1Reported a net loss of $354 million for Q1 2013, primarily due to a $423 million goodwill impairment charge related to the CRM segment following business reorganization.
- 2Net sales decreased by 6% to $1.761 billion, with a 4% decrease on a constant currency basis, excluding divestitures.
- 3Gross profit margin improved to 67.2% from 66.2% in the prior year's quarter, driven by cost efficiencies and product mix.
- 4Company's adjusted net income (excluding impairment charges and other one-time items) was $224 million, or $0.16 per share.
- 5Total debt remained stable at $4.25 billion, with strong compliance with credit facility covenants.
- 6Significant contingent consideration liabilities exist, with a maximum potential future payment of approximately $2.3 billion.
- 7The company is actively managing ongoing litigation, including a significant accrual of $648 million for legal matters.